Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease virus, serotype 1, strain rn1250; live recombinant turkey herpesvirus, expressing the vp2 protein of infectious bursal disease virus, strain vhvt013-69 - immunologicals for aves, domestic fowl, avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus - kana - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (ibd) virus.

Euroopa Liit - eesti - EMA (European Medicines Agency)

intervet international b.v. - live attenuated canine distemper virus strain onderstepoort: 105.1 – 106.5 tcid50, live recombinant canine parvovirus strain 630a: 105.1 – 106.7 tcid50 - immuunväetised koertel - dogs (small) - for the active immunisation of puppies from 4 weeks of age onwards to prevent clinical signs and mortality of canine distemper virus infection and canine parvovirus infection and to prevent viral excretion following canine distemper virus infection and following canine parvovirus infection.

Euroopa Liit - eesti - EMA (European Medicines Agency)

intervet international bv - live bordetella bronchiseptica bakterid tüve b-c2 - immunoloogilised ravimid jaoks felidae, - kassid - 1 kuu vanuste või vanemate kasside aktiivseks immuniseerimiseks, et vähendada bordetella bronchiseptica'ga seotud ülemiste hingamisteede haiguste kliinilisi tunnuseid. immuunsuse tekkimine: immuunsuse tekkimine leiti 8 nädala vanuselt kassile juba 72 tundi pärast vaktsineerimist. immuunsuse kestus: immuunsuse kestus on kuni 1 aasta. ei ole saadaval andmeid ema antikehade mõju kohta nobivac bb-le vaktsineerimisele kassidel. kirjandusest leitakse, et selline ninasisese vaktsiini tüüp on võimeline indutseerima immuunvastust, ilma et see mõjutaks emalt saadud antikehasid.

Euroopa Liit - eesti - EMA (European Medicines Agency)

zoetis belgium sa - live nõrgenenud aujeszky haiguse viirus - immunoloogilised vahendid - sead - sigade aktiivne immuniseerimine alates 10 nädala vanusest, et vältida aujeszky haiguse suremust ja kliinilisi tunnuseid ning vähendada aujeszky haiguse väliuuringu viiruse. vaktsineeritud noorte ja emiste järglaste passiivne immuniseerimine, et vähendada aujeszky haiguse suremust ja kliinilisi tunnuseid ning vähendada aujeszky haiguse põldviiruse eritumist.

Euroopa Liit - eesti - EMA (European Medicines Agency)

gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - viirusevastased ravimid süsteemseks kasutamiseks - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.

Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vaktsiinid - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 ja 4. kasutada dengvaxia peab olema kooskõlas ametlike soovitustega.

Euroopa Liit - eesti - EMA (European Medicines Agency)

intervet international b.v. - raku seotud live rekombinantse türgi herpesvirus (tüvi hvp360), väljendades fusion valk nd viiruse ja vp2 valgu kohta ibd viirus - lindude herpes viirus (marek tõbi) + lindude nakkav bursal haiguse viiruse (gumboro haigus) + newcastle ' i haiguse viiruse/paramyxovirus - chicken; embryonated chicken eggs - for active immunisation of one-day-old chicks or 18-19-day-old embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to prevent mortality and to reduce clinical signs and lesions caused by infectious bursal disease (ibd) virus,to reduce mortality, clinical signs and lesions caused by marek’s disease (md) virus.

Euroopa Liit - eesti - EMA (European Medicines Agency)

bavarian nordic a/s - vibrio cholerae, tüvi cvd 103-hgr, live - cholera - vaktsiinid - vaxchora is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children aged 2 years and older. selle vaktsiini tuleb kasutada vastavalt ametlikele soovitustele.

Euroopa Liit - eesti - EMA (European Medicines Agency)

intervet international b.v. - cell-associated live recombinant turkey herpesvirus (strain hvt/ndv/ilt) expressing the fusion protein of newcastle disease virus and the glycoproteins gd and gi of infectious laryngotracheitis virus - immunoloogilised ained - embryonated chicken eggs; chicken - for active immunisation of one-day-old chicks or embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ilt) virus and marek’s disease (md) virus.

Euroopa Liit - eesti - EMA (European Medicines Agency)

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - immunoloogilised ained - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).